Cliff Asness's ALNY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 919,959 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $365.82 M, representing 0.19% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ALNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 555,759 shares. Largest reduction occurred in Q2 2025, reducing 640,095 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +175,951 | Add 23.65% | 919,959 | $397.65 |
| Q3 2025 | +555,759 | Add 295.23% | 744,008 | $451.62 |
| Q2 2025 | -640,095 | Reduce 77.27% | 188,249 | $325.55 |
| Q1 2025 | +14,988 | Add 1.84% | 828,344 | $262.00 |
| Q4 2024 | +307,702 | Add 60.85% | 813,356 | $235.31 |
| Q3 2024 | +234,035 | Add 86.16% | 505,654 | $274.80 |
| Q2 2024 | +130,482 | Add 92.45% | 271,619 | $242.48 |
| Q1 2024 | +127,117 | Add 906.68% | 141,137 | $149.45 |
| Q4 2023 | +4,560 | Add 48.20% | 14,020 | $191.41 |
| Q3 2023 | +3,726 | Add 64.98% | 9,460 | $175.81 |
| Q2 2023 | -373 | Reduce 6.11% | 5,734 | $189.94 |
| Q1 2023 | +6,107 | New Buy | 6,107 | $198.29 |
| Q4 2022 | -11,768 | Sold Out | 0 | $0.00 |
| Q3 2022 | +5,754 | Add 95.68% | 11,768 | $200.12 |
| Q2 2022 | -5,233 | Reduce 46.53% | 6,014 | $143.83 |
| Q1 2022 | +9,123 | Add 429.52% | 11,247 | $163.33 |
| Q4 2021 | +2,124 | New Buy | 2,124 | $169.49 |
| Q2 2021 | -1,914 | Sold Out | 0 | $0.00 |
| Q1 2021 | -37,733 | Reduce 95.17% | 1,914 | $140.54 |
| Q4 2020 | -32,134 | Reduce 44.77% | 39,647 | $128.51 |
| Q3 2020 | -23,400 | Reduce 24.58% | 71,781 | $144.17 |
| Q2 2020 | +48,963 | Add 105.94% | 95,181 | $148.11 |
| Q1 2020 | +46,218 | New Buy | 46,218 | $108.85 |
| Q2 2019 | -2,367 | Sold Out | 0 | $0.00 |
| Q1 2019 | +2,367 | New Buy | 2,367 | $93.37 |
| Q4 2018 | -9,638 | Sold Out | 0 | $0.00 |
| Q3 2018 | -4,249 | Reduce 30.60% | 9,638 | $87.57 |
| Q2 2018 | -334 | Reduce 2.35% | 13,887 | $98.51 |
| Q1 2018 | +7,676 | Add 117.28% | 14,221 | $119.12 |
| Q4 2017 | +6,545 | New Buy | 6,545 | $127.12 |
| Q1 2017 | -27,669 | Sold Out | 0 | $0.00 |
| Q4 2016 | +27,669 | New Buy | 27,669 | $37.44 |
| Q2 2016 | -3,739 | Sold Out | 0 | $0.00 |
| Q1 2016 | -212,939 | Reduce 98.27% | 3,739 | $62.85 |
| Q4 2015 | +62,887 | Add 40.89% | 216,678 | $94.14 |
| Q3 2015 | +71,679 | Add 87.29% | 153,791 | $80.36 |
| Q2 2015 | +34,764 | Add 73.42% | 82,112 | $119.87 |
| Q1 2015 | +28,979 | Add 157.76% | 47,348 | $104.42 |
| Q4 2014 | -11,900 | Reduce 39.31% | 18,369 | $97.01 |
| Q3 2014 | +2,264 | Add 8.08% | 30,269 | $78.10 |
| Q2 2014 | +6,800 | Add 32.07% | 28,005 | $63.17 |
| Q1 2014 | -2,200 | Reduce 9.40% | 21,205 | $67.15 |
| Q4 2013 | -20,878 | Reduce 47.15% | 23,405 | $64.35 |
| Q3 2013 | -211 | Reduce 0.47% | 44,283 | $64.02 |
| Q2 2013 | +44,494 | Add 0.00% | 44,494 | $31.02 |
| Q4 2012 | +35,494 | Add 0.00% | 35,494 | $18.26 |
Cliff Asness's Alnylam Pharmaceuticals Investment FAQs
Cliff Asness first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q4 2012, acquiring 35,494 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Alnylam Pharmaceuticals, Inc. (ALNY) for 47 quarters since Q4 2012.
Cliff Asness's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2025, adding 744,008 shares worth $336.01 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 919,959 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $365.82 M.
As of the Q4 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.19% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 919,959 shares, as reported at the end of Q4 2025.